David McCormick Ph.D.
Research & Accomplishments
My research program is focused on the preclinical development of drugs, natural products, and hormonal manipulations for the prevention and therapy of cancer. Studies are conducted in animal models for cancer of the breast, prostate, lung, oral cavity, skin, urinary bladder, and hematopoietic system, as well as in preclinical models for drug safety assessment. Research in areas other than cancer prevention and therapy includes studies to evaluate the possible health effects of non-ionizing radiation (radiofrequency [cell phone] and 60 Hz [power frequency] magnetic fields), preclinical safety assessments of novel therapeutics, and studies in the general area of environmental toxicology.
- Cancer biology
- Preclinical drug development
- Biological effects of non-ionizing radiation
- National Institute of Environmental Health Sciences (National Toxicology Program), N01-ES-55544, Studies to Evaluate the Toxic and Carcinogenic Potential of Cell Phone Radiofrequency Radiation, 2005-2014, $25,019,697
- National Cancer Institute, N01-CM-42202, Preclinical Toxicology and Pharmacology of Drugs Developed for Cancer, AIDS, and AIDS-related Illnesses, 2004-2012, $18,587,693
- National Cancer Institute, N01-CN-43303, Preclinical In Vitro and In Vivo Screening Assays for Cancer Preventive Agent Development, 2004-2012, $6,552,116
- National Cancer Institute, N01-CM-2011-00027, Preclinical Toxicology of Drugs Developed for Cancer and Other Diseases, 2011-2016, $10,968,029
- United States Public Health Service Predoctoral Fellowship in Environmental Health Sciences, New York University, 1974 to 1976
- United States Department of Health and Human Services, National Cancer Institute, New Investigator Research Award, 1982 to 1985
- Diplomate, American Board of Toxicology, 1983; recertified 1988, 1993, 1998, 2003, 2008
- IIT Research Institute Presidential Award for Science and Technology, 2000
- American College of Toxicology President's Award, for "Best Paper Published in the International Journal of Toxicology", 2004
"Subchronic oral toxicity and metabolite profiling of the p53 stabilizing agent, CP-31398, in rats and dogs." Toxicology, in press, 2011. W.D. Johnson, M. Muzzio, C.J. Detrisac, I.M. Kapetanovic, L. Kopelovich, and D.L. McCormick.
"Subchronic oral toxicity and cardiovascular safety pharmocology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity." J. Food Chem. Toxicol., in press, 2011. W.D. Johnson, R.L. Morrissey, A.L. Usborne, I. Kapetanovic, J.A. Crowell, M. Muzzio, and D.L. McCormick.
"Animal Studies in Carcinogen Identification: The Example of Power Frequency (50/60 Hz) Magnetic Fields." In: Cancer Risk Evaluation: Methods and Trends, G. Obe, B. Jandrig, G. Marchant, H. Schütz, and P. Wiedemann (Eds.), Wiley-VCH, Berlin, 2011, pp. 125-136. D.L. McCormick.
“Overexpression of COX-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and non-selective COX Inhibitors.” Cancer Prevention Res., 3, 73-81, 2010. D. L. McCormick, J. M. Phillips, T. L. Horn, W. D. Johnson, V. E. Steele, and R. A. Lubet.
Murine oncogenicity and pharmacokinetics evaluations of 9-cis-UAB30, a new retinoid for breast cancer chemoprevention." Int. J. Toxicol., 29, 157-164, 2010. I.M. Kapetanovic, T.L. Horn, W.D. Johnson, M.J. Cwik, C.J. Detrisac, and D.L. McCormick.
"Integration of in vivo and in vitro approaches to characterize the toxicity of Antalarmin, a corticotrophin-releasing hormone receptor agonist." Toxicology, 248, 8-17, 2008. T. L. Horn, J. B. Harder, W. D. Johnson, P. T. Curry, R. E. Parchment, R. L. Morrissey, P. W. Mellick, K. A. Calis, P. W. Gold, K. C. Rice, C. Contoreggi, D. S. Charney, G. Cizzo, E. R. Glaze, J. E. Tomaszewski, and D. L. McCormick.
"Chemoprevention of rat prostate carcinogenesis by 16α-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone". Carcinogenesis, 28: 398-403, 2007. D. L. McCormick, W. D. Johnson, N. M. Kozub, K. V. N. Rao, R. A. Lubet, V. E. Steele, and M. C. Bosland.
"Subchronic toxicity and toxicogenomic evaluation of tamoxifen citrate + bexarotene in female rats." Toxicol. Sci., 99, 612-627, 2007. T. L. Horn, K. E. O. Torres, J. M. Naylor, M. J. Cwik, C. J. Detrisac, I. M. Kapetanovic, R. A. Lubet, J. A. Crowell, and D.L. McCormick.
"Modulation of Hepatic and Renal Drug Metabolizing Enzyme Systems in Rats by Subchronic Administration of Farnesol". Chem. Biol. Interact., 252: 79-99, 2005. T. L. Horn, L. Long, M. J. Cwik, R. L. Morrissey, I. M. Kapetanovic, and D. L. McCormick.
"Modulation of Hepatic and Renal Drug Metabolizing Enzyme Systems in Rats by Subchronic Administration of Farnesol." Chem. Biol. Interact., 252:79-99, 2005. T.L. Horn, L. Long, M.J. Cwik, R.L. Morrissey, I.M. Kapetanovic, and D.L. McCormick.
"Animal Models for the Study of Childhood Leukemia: Considerations for Model Identification and Optimization to Identify Potential Risk Factors". Int. J. Toxicol., 23: 149-161, 2004. D. L. McCormick and R. Kavet. [Winner of the 2004 "Best Paper" Award from the American College of Toxicology]
- Toxicology - Editorial Board
- Nutrition and Cancer - Editorial Board
- Public Library of Science One - Academic Editor
- American Association for Cancer Research
- Society of Toxicology
- American College of Toxicology
- Society for Experimental Biology and Medicine
- International Association for Breast Cancer Research
- Since 1982, my research programs have been funded by more than 40 grants and contracts from the National Cancer Institute, National Institute of Environmental Health Sciences, and other branches of the NIH.